Prithvi Mruthyunjaya, MD, MHS

Cancer.Net Specialty Editor: Eye Cancers
Byers Eye Institute at Stanford, Palo Alto, CA

Dr. Prithvi Mruthyunjaya is a board-certified ophthalmologist, an Associate Professor of Ophthalmology at Stanford University, a member of the Vitreoretinal Surgery Service, and the Director of Ocular Oncology at the Byers Eye Institute. Dr. Mruthyunjaya was selected for the highly prestigious accelerated 6-year medical program, completing his undergraduate studies at Rensselaer in 2 years then moving on to complete his medical studies at Albany Medical College where he was elected to the Alpha Omega Alpha honor society. At the Duke Eye Center in Durham, NC, he finished his Ophthalmology residency, Chief Residency, and clinical-research fellowships in Vitreoretinal surgery followed by an Ocular Oncology fellowship at the Moorfields Eye Hospital in London, UK. As a fellow, he was recognized with the highest nationwide honors by the Heed, AOS-Knapp, and Ronald G Michels foundations. He was recently listed as one of the world’s 150 most innovative retinal specialists.

Dr. Mruthyunjaya cares for patients with conditions related to cancer of the eye in both adults and children -- either benign, pre-cancerous, or eye cancer. These conditions include ocular melanoma, hemangioma, cancers from other parts of the body which spread to the eye, Coats' disease, retinoblastoma, iris tumors (melanoma, cysts, metastatic lesions) and tumors of the conjunctiva including melanoma, and squamous cells carcinoma. He also manages the eye-related side effects of chemotherapy treatments. He uses advanced diagnostic tests to make a personalized treatment plan for every patient. With his expertise in retinal surgery, he treats patients with a variety of advanced techniques, including small instrument tumor biopsy, vitrectomy, and radiation therapy.

Dr. Mruthyunjaya provides customized care for every patient and works closely with other experts at the Stanford Cancer Institute. Dr. Mruthyunjaya is actively involved in research in ocular cancer imaging, genetics, and new modalities of tumor biopsy.  His passion lies in developing collaborative research networks and training the next generation of vitreoretinal surgeons.

View current ASCO disclosure here.

Last updated: November 2019